Indication: Bladder Cancer
A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
Adv Urothelial w/selected FGFR gene aberrations
Sub-indication: Metastatic or surgically unresectable urothelial Carcinoma with FGFR mutation
Line of Therapy: 2nd line, must have progressed on first line therapy and have one of the protocol defined FGFR translocations or mutations per central lab analysis.
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Janssen Research & Development
Email for more information: GU-NCIResearch@nortonhealthcare.org